RT Journal Article
SR Electronic
A1 Vinall, Phil
T1 Cangrelor Offers Protective Benefits in PCI Patients
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 2
SP 16
OP 17
DO 10.1177/155989771302008
UL http://mdc.sagepub.com/content/13/2/16.2.abstract
AB Cangrelor, an intravenous, potent, direct-acting adenosine diphosphate (ADP) receptor antagonist, significantly reduced the composite endpoint of death, myocardial infarction (MI), ischemia-driven revascularization, and stent thrombosis in patients undergoing percutaneous coronary intervention (PCI) with no excess in severe bleeding compared with clopidogrel loading at the time of PCI. This article presents the results of the Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [CHAMPION PHOENIX; Bhatt DL et al. N Engl J Med 2013] in a late-breaking clinical trial.